A New Frontier in Immuno-Oncology
Management Team
President, CEO, and Cofounder
Chief Development Officer
Vice President of Research and Cofounder
Executive Director, Translational and Clinical Sciences
Chief Medical Advisor
Head of Operations
Scientific Advisory Board
Greg Barton, Ph.D.
Paul Rennert, Ph.D.
Samuel Miller, M.D.
Denise Monack, Ph.D.
Mario Sznol, M.D.
Clinical Advisory Board
Jean Pierre Bizzari, M.D.
Joel Randolph Hecht, M.D.
Jason Luke, M.D.
Mario Sznol, M.D.
News
BERKELEY, Calif., Nov. 12, 2021
BERKELEY, Calif., Nov. 11, 2021
BERKELEY, Calif., May 26, 2021
Dr. Laura Hix Glickman, Cofounder and Vice President of Research, has been invited to speak at the STING & TLR-Targeting Therapies Digital Summit on May 26, 2021
BERKELEY, Calif., January 13, 2021
Newly Appointed Members Include Dr. Lawrence Fong, M.D. and Dr. Michel Streuli, Ph.D.
BERKELEY, Calif., April 27, 2020
Financing will fund Actym’s cancer immunotherapy pipeline into clinical development
BERKELEY, Calif., Nov 7, 2019 PRNewswire
The presentation will highlight Actym’s novel tumor-specific therapies that deliver multiplexed immunomodulatory payloads after systemic administration.
BERKELEY, Calif., April 10, 2019
Actym Therapeutics announced that Dr. Christopher Thanos, President, CEO, and Cofounder, has been invited to speak at the 15th annual PEGS Conference in Boston, MA.
Apr 02, 2019 PRNewswire
Two presentations will highlight Actym's novel IV administered, tumor-infiltrating therapies that express immuno-modulatory factors
Nov 8, 2018 PRNewswire
Presentation will focus on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor efficacy in multiple murine cancer models.
